BioPharma Dive – AI / Data
Lilly’s three-pronged obesity drug hits goal in large diabetes trial
Retatrutide, a possible advance on GLP-1 drugs like Zepbound, significantly cut blood sugar and body weight in the study, a sign it might be similarly impactful against obesity.